273753-64-3

Upstream product

• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 3282-30-2 pivaloyl chloride 
• 3128-06-1 5-ketohexanoic acid 
• 134916-00-0 (4S)-4-benzyl-3-(hex-5-enoyl)-1,3-oxazolidin-2-one 
• 101711-90-4 (S)-4-benzyl-2-oxazolidinone lithium salt 

Downstream Products

• 273753-65-4 (S)-4-Benzyl-3-[4-(2-methyl-[1,3]dithiolan-2-yl)-butyryl]-oxazolidin-2-one 
• 287717-24-2 (S)-4-Benzyl-3-[4-(2-methyl-[1,3]dithian-2-yl)-butyryl]-oxazolidin-2-one 
• 187148-13-6 (-)-sanglifehrin A 
• 287717-25-3 (R)-1-((S)-4-Benzyl-2-oxo-oxazolidin-3-yl)-2-[2-(2-methyl-[1,3]dithian-2-yl)-ethyl]-pentane-1,3-dione 
• 428874-15-1 (S)-4-Benzyl-3-{(3S,4S,5R,6R)-3-[(1E,3E,7E)-(S)-6-(tert-butyl-dimethyl-silanyloxy)-8-iodo-7-methyl-octa-1,3,7-trienyl]-1,4-dimethyl-2,9-dioxa-bicyclo[3.3.1]nonane-6-carbonyl}-oxazolidin-2-one 
• 428874-13-9 (S)-4-Benzyl-3-{(3S,4S,5R,6R)-3-[(1E,3E)-(S)-6-(tert-butyl-diphenyl-silanyloxy)-octa-1,3-dien-7-ynyl]-1,4-dimethyl-2,9-dioxa-bicyclo[3.3.1]nonane-6-carbonyl}-oxazolidin-2-one 
• 287717-36-6 (S)-4-Benzyl-3-{(6E,8E,12E)-(2R,3R,4S,5S,11S)-11-(tert-butyl-dimethyl-silanyloxy)-3,5-dihydroxy-13-iodo-4,12-dimethyl-2-[2-(2-methyl-[1,3]dithian-2-yl)-ethyl]-trideca-6,8,12-trienoyl}-oxazolidin-2-one 
• 1026273-04-0 (6E,8E,12E)-(2R,4S,5S,11S)-1-((S)-4-Benzyl-2-oxo-oxazolidin-3-yl)-11-(tert-butyl-dimethyl-silanyloxy)-5-hydroxy-13-iodo-4,12-dimethyl-2-[2-(2-methyl-[1,3]dithian-2-yl)-ethyl]-trideca-6,8,12-triene-1,3-dione 
• 287717-28-6 (6E,8E)-(2R,4S,5S,11S)-1-((S)-4-Benzyl-2-oxo-oxazolidin-3-yl)-11-(tert-butyl-diphenyl-silanyloxy)-5-hydroxy-4-methyl-2-[2-(2-methyl-[1,3]dithian-2-yl)-ethyl]-trideca-6,8-dien-12-yne-1,3-dione 
• 287717-29-7 (S)-4-Benzyl-3-{(6E,8E)-(2R,3R,4S,5S,11S)-11-(tert-butyl-diphenyl-silanyloxy)-3,5-dihydroxy-4-methyl-2-[2-(2-methyl-[1,3]dithian-2-yl)-ethyl]-trideca-6,8-dien-12-ynoyl}-oxazolidin-2-one 
• 382139-08-4 1-[3-(3-tert-butoxycarbonyloxy-phenyl)-2-(2-{[3-(6-hydroxy-8-iodo-7-methyl-octa-1,3,7-trienyl)-1,4-dimethyl-2,9-dioxa-bicyclo[3.3.1]nonane-6-carbonyl]-amino}-3-methyl-butyrylamino)-propionyl]-hexahydro-pyridazine-3-carboxylic acid methyl ester 
• 382139-23-3 1-[3-(3-tert-butoxycarbonyloxy-phenyl)-2-(2-{[3-(6-hydroxy-8-iodo-7-methyl-octa-1,3,7-trienyl)-1,4-dimethyl-2,9-dioxa-bicyclo[3.3.1]nonane-6-carbonyl]-amino}-3-methyl-butyrylamino)-propionyl]-hexahydro-pyridazine-3-carboxylic acid 
• 382139-10-8 C₃₈H₅₁IN₄O₈ 
• 428874-22-0 3-(3-tert-butoxycarbonyloxy-phenyl)-2-(2-{[3-(6-hydroxy-8-iodo-7-methyl-octa-1,3,7-trienyl)-1,4-dimethyl-2,9-dioxa-bicyclo[3.3.1]nonane-6-carbonyl]-amino}-3-methyl-butyrylamino)-propionic acid 2-trimethylsilanyl-ethyl ester 

Relevant academic research and scientific papers

Highly diastereocontrolled synthesis of the C1-C25 domain of sanglifehrin A

We report a diastereoselective synthesis of 2 containing the core structure of the entire eastern sector of sanglifehrin A. The route proceeds by directed chain extension of appropriate building blocks, their timely convergent amalgamation, and ultimate c

Integrin receptor antagonists

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 an

A convergent three-component total synthesis of the powerful immunosuppressant (-)-sanglifehrin A

The potent immunosuppressive agent (-)-sanglifehrin A (5), initially discovered in a soil sample from Malawi, has been synthesized in a highly conver soil gent and stereocontrolled manner. The enantioselective approach relies on initial construction of th

A stereoselective synthesis of the C13-C19 fragment of sanglifehrin A

A short, stereoselective route to the C13-C19 fragment of the immunosuppressant sanglifehrin A 1, is presented. The key step involves a highly diastereoselective boron aldol reaction between β-ketoimide 11 and triisopropylsilyl propargyl aldehyde 21c.